3-V Biosciences To Present Data on HCV Product Candidates at the American Association for the Study of Liver Disease Annual Meeting 2012
Small Molecule FASN Inhibitors Demonstrate Antiviral Activity
MENLO PARK, Calif. , Oct. 1, 2012 /PRNewswire/ -- 3-V Biosciences, Inc., announced today that two abstracts have been accepted for presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 9-13 in Boston, Massachusetts.
(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)
3-V Biosciences is discovering and developing oral antiviral therapeutics designed to have broad-spectrum activity and a high barrier to resistance. Data characterizing the preclinical antiviral activity of the company's novel small molecules targeting the fatty acid synthase ( FASN) pathway for the potential treatment of chronic hepatitis C virus ( HCV) infection will be featured in oral and poster presentations.
Oral Presentation
Sunday, November 11, 2012 at 5:30pm ET:
HCV Therapy: Preclinical and Early Clinical Development
" Potent Hepatitis C Antiviral Activity By Inhibiting Fatty Acid
Synthase"
(Parallel 13, Hynes: Room 21)
Poster Presentation (Presidential Poster of Distinction
award)
Tuesday, November 13, 2012 from 8:00am - 12:00pm ET:
HCV Therapy: Preclinical and Early Clinical Development
"TVB-2640, a Novel Anti-HCV Agent, Safely Causes Sustained
Host-Target Inhibition in Vivo"
(Poster Hall, #1876)
About FASN
FASN is a cellular enzyme implicated in HCV replication and several
cancers. First-generation FASN inhibitors have shown preclinical
benefits in a variety of viral infections, including HCV, as well
as in models of pancreatic, prostatic, breast and colorectal
tumors, but their development has been hindered by poor
bioavailability and systemic tolerability. 3-V has discovered and
is advancing proprietary FASN inhibitors with pharmaceutical
properties that overcome the shortcomings of earlier generations of
inhibitors, and have the potential to become potent therapeutics
for chronic HCV and other indications.
About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company
that discovers and develops antiviral therapeutics designed to have
broad-spectrum activity, including efficacy against viruses
resistant to other classes of antiviral drugs, and a high barrier
to resistance. The 3-V team applies an integrated approach with
internal expertise in virology, biology, drug discovery and
development to drive programs forward. The company is located in
Menlo Park, California.
For additional information on 3-V Biosciences, please visit www.3vbio.com.
Contact information
Stephen R. Brady
Chief Business Officer
650-561-8600
Media Inquiries
BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
kbergman@bccpartners.com
Michelle Corral
415-794-8662
mcorral@bccpartners.com
SOURCE 3-V Biosciences, Inc.
Web Site: http://www.3vbio.com
Posted: October 2012
